Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.
Chief Executive Officer Vladislav Sandler says: "I am excited by the decision of the United States Patent and Trademark Office to allow this patent application. This is a significant addition to the patent protection for CDX which remains one of our key product candidates for the future. This also solidifies our company's position as a leader in the area of conditioning bone marrow transplants."
Current stock price: 3.81 pence, up 12% in London on Friday morning
12-month change: up 64%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Hemogenyx (HEMO)